37,938 Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Purchased by Bleakley Financial Group LLC

Bleakley Financial Group LLC acquired a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 37,938 shares of the company’s stock, valued at approximately $33,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KPTI. Advisor Group Holdings Inc. increased its position in shares of Karyopharm Therapeutics by 134.3% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,906 shares of the company’s stock worth $30,000 after purchasing an additional 5,105 shares during the last quarter. Prelude Capital Management LLC purchased a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $53,000. Alpine Global Management LLC purchased a new position in Karyopharm Therapeutics during the 4th quarter valued at about $58,000. PEAK6 Investments LLC purchased a new position in Karyopharm Therapeutics during the 1st quarter valued at about $58,000. Finally, State of Wyoming boosted its holdings in Karyopharm Therapeutics by 188.8% during the 4th quarter. State of Wyoming now owns 17,082 shares of the company’s stock valued at $58,000 after acquiring an additional 11,168 shares during the period. 66.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.67.

Insider Transactions at Karyopharm Therapeutics

In other news, CFO Michael Mason sold 27,687 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $32,393.79. Following the sale, the chief financial officer now owns 404,918 shares of the company’s stock, valued at approximately $473,754.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Karyopharm Therapeutics news, CFO Michael Mason sold 27,687 shares of Karyopharm Therapeutics stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $32,393.79. Following the transaction, the chief financial officer now owns 404,918 shares of the company’s stock, valued at $473,754.06. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Richard A. Paulson sold 80,470 shares of Karyopharm Therapeutics stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total value of $94,149.90. Following the transaction, the chief executive officer now directly owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 164,542 shares of company stock valued at $198,175. Corporate insiders own 3.32% of the company’s stock.

Karyopharm Therapeutics Stock Performance

Shares of KPTI opened at $1.10 on Wednesday. The stock has a 50-day simple moving average of $1.35 and a 200-day simple moving average of $1.05. The stock has a market capitalization of $126.58 million, a PE ratio of -0.88 and a beta of 0.03. Karyopharm Therapeutics Inc. has a 1 year low of $0.62 and a 1 year high of $4.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $33.75 million during the quarter, compared to analyst estimates of $33.50 million. During the same quarter in the previous year, the business earned ($0.43) earnings per share. Analysts predict that Karyopharm Therapeutics Inc. will post -1.19 EPS for the current year.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).